Physiologically relevant fluorescent assay for identification of 17β‐hydroxysteroid dehydrogenase type 10 inhibitors

Abstract

AbstractMitochondrial enzyme 17β‐hydroxysteroid dehydrogenase type 10 (HSD10) is a potential molecular target for treatment of mitochondrial‐related disorders such as Alzheimer's disease (AD). Its over‐expression in AD brains is one of the critical factors disturbing the homeostasis of neuroprotective steroids and exacerbating amyloid beta (Aβ)‐mediated mitochondrial toxicity and neuronal stress. This study was focused on revalidation of the most potent HSD10 inhibitors derived from benzothiazolyl urea scaffold using fluorescent‐based enzymatic assay with physiologically relevant substrates of 17β‐oestradiol and allopregnanolone. The oestradiol‐based assay led to the identification of two nanomolar inhibitors (IC50 70 and 346 nM) differing from HSD10 hits revealed from the formerly used assay. Both identified inhibitors were found to be effective also in allopregnanolone‐based assay with non‐competitive or uncompetitive mode of action. In addition, both inhibitors were confirmed to penetrate the HEK293 cells and they were able to inhibit the HSD10 enzyme in the cellular environment. Both molecules seem to be potential lead structures for further research and development of HDS10 inhibitors.image